{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:03:17Z","timestamp":1740106997367,"version":"3.37.3"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s00520-021-06116-w","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T23:02:28Z","timestamp":1616626948000},"page":"6193-6200","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Latent infection screening and prevalence in cancer patients born outside of Australia: a universal versus risk-based approach?"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9561-3592","authenticated-orcid":false,"given":"Gemma","family":"Reynolds","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabrielle","family":"Haeusler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica A.","family":"Slavin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Teh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Thursky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,24]]},"reference":[{"key":"6116_CR1","doi-asserted-by":"crossref","unstructured":"Baden LR, Swaminathan S, Angarone M, Blouin G, Camins BC, Casper C, et al. (2016) Prevention and treatment of cancer-related infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. 14(7):882","DOI":"10.6004\/jnccn.2016.0093"},{"issue":"4","key":"6116_CR2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1001\/jamaoncol.2018.6437","volume":"5","author":"SD Ramsey","year":"2019","unstructured":"Ramsey SD, Unger JM, Baker LH, Little RF, Loomba R, Hwang JP, Chugh R, Konerman MA, Arnold K, Menter AR, Thomas E, Michels RM, Jorgensen CW, Burton GV, Bhadkamkar NA, Hershman DL (2019) Prevalence of hepatitis B virus, hepatitis C virus, and HIV infection among patients with newly diagnosed cancer from academic and community oncology practices. JAMA Oncol 5(4):497\u2013505","journal-title":"JAMA Oncol"},{"key":"6116_CR3","doi-asserted-by":"crossref","unstructured":"Kurizky PS, dos Santos Neto LL, Aires RB, da Mota LMH, Gomes CM (2020) Opportunistic tropical infections in immunosuppressed patients. Best Pract Res Clin Rheumatol 101509","DOI":"10.1016\/j.berh.2020.101509"},{"key":"6116_CR4","unstructured":"2019 HBMDCTCSG. Hepatitis B management during immunosuppression for haematological and solid-organ malignancies: an Australian consensus statement 2019 Melbourne2019"},{"issue":"suppl 59","key":"6116_CR5","first-page":"PA2985","volume":"46","author":"S Menzies","year":"2015","unstructured":"Menzies S, Curry L, Turnbull C (2015) Active TB in cancer patients: a missed screening opportunity? Eur Respir J 46(suppl 59):PA2985","journal-title":"Eur Respir J"},{"issue":"1","key":"6116_CR6","doi-asserted-by":"publisher","first-page":"11901","DOI":"10.1038\/s41598-019-48395-8","volume":"9","author":"C-C Shu","year":"2019","unstructured":"Shu C-C, Liao K-M, Chen Y-C, Wang J-J, Ho C-H (2019) The burdens of tuberculosis on patients with malignancy: incidence, mortality and relapse. Sci Rep 9(1):11901","journal-title":"Sci Rep"},{"issue":"8","key":"6116_CR7","doi-asserted-by":"publisher","first-page":"e0220108","DOI":"10.1371\/journal.pone.0220108","volume":"14","author":"D Raben","year":"2019","unstructured":"Raben D, Sullivan AK, Mocroft A, Kutsyna G, Had\u017eiosmanovi\u0107 V, Vassilenko A, Chkhartisvili N, Mitsura V, Pedersen C, Anderson J, Begovac J, Bak Dragsted U, Bertisch B, Grzeszczuk A, Minton J, Necsoi VC, Kitchen M, Ajana F, Sokhan A, Comi L, Farazmand P, Pesut D, de Wit S, Gatell JM, Gazzard B, d\u2019Arminio Monforte A, Rockstroh JK, Yazdanpanah Y, Champenois K, Jakobsen ML, Lundgren JD, on behalf of the HIDES Study Group (2019) Improving the evidence for indicator condition guided HIV testing in Europe: results from the HIDES II Study \u2013 2012 \u2013 2015. PLoS One 14(8):e0220108","journal-title":"PLoS One"},{"issue":"6","key":"6116_CR8","first-page":"678","volume":"4","author":"J Molto","year":"2015","unstructured":"Molto J, Moran T, Sirera G, Clotet B (2015) Lung cancer in HIV-infected patients in the combination antiretroviral treatment era. Transl Lung Cancer Res 4(6):678\u2013688","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"6116_CR9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/1753-6405.12934","volume":"44","author":"JH MacLachlan","year":"2020","unstructured":"MacLachlan JH, Romero N, Higgins N, Coutts R, Chan R, Stephens N et al (2020) Epidemiology of chronic hepatitis B and C in Victoria, Australia: insights and impacts from enhanced surveillance. Aust N Z J Public Health 44(1):59\u201364","journal-title":"Aust N Z J Public Health"},{"issue":"4","key":"6116_CR10","first-page":"501","volume":"15","author":"C Yang","year":"2016","unstructured":"Yang C, Qin B, Yuan Z, Chen L (2016) Zhou H-y. Meta-analysis of prophylactic entecavir or lamivudine against hepatitis B virus reactivation. Ann Hepatol 15(4):501\u2013511","journal-title":"Ann Hepatol"},{"key":"6116_CR11","first-page":"CD001363","volume":"2","author":"MJ Smieja","year":"2000","unstructured":"Smieja MJ, Marchetti CA, Cook DJ, Smaill FM (2000) Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2:CD001363","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"6116_CR12","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1506816","volume":"373","author":"Group ISS","year":"2015","unstructured":"Group ISS (2015) Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 373(9):795\u2013807","journal-title":"N Engl J Med"},{"key":"6116_CR13","first-page":"72","volume":"2","author":"O Alshuwaykh","year":"2020","unstructured":"Alshuwaykh O, Kwo PY (2020) HCV treatment in 2020: how to translate highly effective therapies into elimination strategies. Hepatology. 2:72\u201374","journal-title":"Hepatology."},{"issue":"4","key":"6116_CR14","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1053\/j.gastro.2019.01.271","volume":"157","author":"HA Torres","year":"2019","unstructured":"Torres HA, Pundhir P, Mallet V (2019) Hepatitis C virus infection in patients with cancer: impact on clinical trial enrollment, selection of therapy, and prognosis. Gastroenterology. 157(4):909\u2013916","journal-title":"Gastroenterology."},{"key":"6116_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/CCI.18.00097","volume":"3","author":"JP Hwang","year":"2019","unstructured":"Hwang JP, Huang D, Vierling JM, Suarez-Almazor ME, Shih Y-CT, Chavez-MacGregor M et al (2019) Cost-effectiveness analysis of hepatitis b virus screening and management in patients with hematologic or solid malignancies anticipating immunosuppressive cancer therapy. JCO Clin Cancer Inform 3:1\u201312","journal-title":"JCO Clin Cancer Inform"},{"key":"6116_CR16","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1200\/JOP.2015.005116","volume":"11","author":"J Hwang","year":"2015","unstructured":"Hwang J, Granwehr B, Torres H (2015) HIV testing in patients with cancer at the initiation of therapy at a large US comprehensive cancer center. J Oncol Pract 11:384\u2013390","journal-title":"J Oncol Pract"},{"issue":"5","key":"6116_CR17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3322\/caac.21403","volume":"67","author":"HA Torres","year":"2017","unstructured":"Torres HA, Shigle TL, Hammoudi N, Link JT, Samaniego F, Kaseb A, Mallet V (2017) The oncologic burden of hepatitis C virus infection: a clinical perspective. CA Cancer J Clin 67(5):411\u2013431","journal-title":"CA Cancer J Clin"},{"issue":"19","key":"6116_CR18","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1200\/JCO.2015.61.3745","volume":"33","author":"JP Hwang","year":"2015","unstructured":"Hwang JP, Somerfield MR, Alston-Johnson DE, Cryer DR, Feld JJ, Kramer BS, Sabichi AL, Wong SL, Artz AS (2015) Hepatitis B virus screening for patients with cancer before therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update. J Clin Oncol 33(19):2212\u20132220","journal-title":"J Clin Oncol"},{"key":"6116_CR19","unstructured":"ASHM. HBV Testing Policy. In: Committee ER, editor. 2020"},{"issue":"1","key":"6116_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HLY, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH (2016) Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 10(1):1\u201398","journal-title":"Hepatol Int"},{"issue":"5","key":"6116_CR21","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S1473-3099(16)00118-3","volume":"16","author":"V Mallet","year":"2016","unstructured":"Mallet V, van Bommel F, Doerig C, Pischke S, Hermine O, Locasciulli A et al (2016) Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). Lancet Infect Dis 16(5):606\u2013617","journal-title":"Lancet Infect Dis"},{"key":"6116_CR22","doi-asserted-by":"crossref","unstructured":"Hwang JP, Feld JJ, Hammond SP, Wang SH, Alston-Johnson DE, Cryer DR, et al. (2020) Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. J Clin Oncol. JCO2001757","DOI":"10.1200\/JCO.20.01757"},{"issue":"4","key":"6116_CR23","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM et al (2018) Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 67(4):1560\u20131599","journal-title":"Hepatology."},{"key":"6116_CR24","unstructured":"Diseases AAftSoL (2014) AASLDIDSA Recommendations for testing, managing, and treating hepatitis C"},{"issue":"2","key":"6116_CR25","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"Liver EAFTSOT","year":"2017","unstructured":"Liver EAFTSOT (2017) EASL 2017 Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol 67(2):370\u2013398","journal-title":"J Hepatol"},{"issue":"2","key":"6116_CR26","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"Liver EAfTSoT","year":"2018","unstructured":"Liver EAfTSoT (2018) EASL recommendations on treatment of hepatitis C 2018. J Hepatol 69(2):461\u2013511","journal-title":"J Hepatol"},{"issue":"RR-14","key":"6116_CR27","first-page":"1","volume":"55","author":"BM Branson","year":"2006","unstructured":"Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB et al (2006) Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 55(RR-14):1\u201317 quiz CE1-4","journal-title":"MMWR Recomm Rep"},{"issue":"1_suppl","key":"6116_CR28","doi-asserted-by":"publisher","first-page":"189S","DOI":"10.1177\/0033354920930146","volume":"135","author":"S Salvant Valentine","year":"2020","unstructured":"Salvant Valentine S, Caldwell J, Tailor A (2020) Effect of CDC 2006 Revised HIV testing recommendations for adults, Adolescents, pregnant women, and newborns on state laws, 2018. Public Health Rep 135(1_suppl):189S\u2013196S","journal-title":"Public Health Rep"},{"issue":"3","key":"6116_CR29","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1136\/archdischild-2016-310870","volume":"102","author":"L Turnbull","year":"2017","unstructured":"Turnbull L, Bell C, Child F (2017) Tuberculosis (NICE clinical guideline 33). Arch Dis Child Educ Pract Ed 102(3):136\u2013142","journal-title":"Arch Dis Child Educ Pract Ed"},{"issue":"2","key":"6116_CR30","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw694","volume":"64","author":"DM Lewinsohn","year":"2017","unstructured":"Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E et al (2017) Official American Thoracic Society\/Infectious Diseases Society of America\/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis 64(2):e1\u2013e33","journal-title":"Clin Infect Dis"},{"issue":"10","key":"6116_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13406","volume":"73","author":"R Sullivan","year":"2019","unstructured":"Sullivan R, Gaskell C, Lewis CR, Vollmer-Conna U, Post JJ (2019) Infectious disease screening in patients prior to undergoing immunosuppressive therapy. Int J Clin Pract 73(10):e13406","journal-title":"Int J Clin Pract"},{"issue":"1","key":"6116_CR32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12879-017-2908-5","volume":"18","author":"AM Falla","year":"2018","unstructured":"Falla AM, Ahmad AA, Duffell E, Noori T, Veldhuijzen IK (2018) Estimating the scale of chronic hepatitis C virus infection in the EU\/EEA: a focus on migrants from anti-HCV endemic countries. BMC Infect Dis 18(1):42","journal-title":"BMC Infect Dis"},{"key":"6116_CR33","unstructured":"Global H. AIDS statistics: 2019 Factsheet. UNAIDS. 2019."},{"issue":"1","key":"6116_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cld.2009.11.009","volume":"14","author":"HS Te","year":"2010","unstructured":"Te HS, Jensen DM (2010) Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 14(1):1\u201321","journal-title":"Clin Liver Dis"},{"key":"6116_CR35","volume-title":"Mandell, Douglas, and Bennett\u2019s principles and practice of infectious diseases. Ninth ed.","author":"JE Bennett","year":"2020","unstructured":"Bennett JE, Dolin R, Blaser MJ (2020) Mandell, Douglas, and Bennett\u2019s principles and practice of infectious diseases. Ninth ed. Elsevier, Philadelphia"},{"issue":"9","key":"6116_CR36","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/jvh.12913","volume":"25","author":"G Angelidakis","year":"2018","unstructured":"Angelidakis G, Hwang JP, Dandachi D, Economides MP, Hosry J, Granwehr BP, Torres HA (2018) Universal screening for hepatitis C: a needed approach in patients with haematologic malignancies. J Viral Hepat 25(9):1102\u20131104","journal-title":"J Viral Hepat"},{"issue":"2","key":"6116_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116978","volume":"10","author":"W-C Sun","year":"2015","unstructured":"Sun W-C, Hsu P-I, Yu H-C, Lin K-H, Tsay F-W, Wang H-M, Tsai TJ, Chen WC, Lai KH, Cheng JS (2015) The compliance of doctors with viral hepatitis B screening and antiviral prophylaxis in cancer patients receiving cytotoxic chemotherapy using a hospital-based screening reminder system. PLoS One 10(2):e0116978","journal-title":"PLoS One"},{"issue":"24","key":"6116_CR38","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1200\/JCO.2011.35.1635","volume":"29","author":"FL Day","year":"2011","unstructured":"Day FL, Karnon J, Rischin D (2011) Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors. J Clin Oncol 29(24):3270\u20133277","journal-title":"J Clin Oncol"},{"issue":"3","key":"6116_CR39","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1001\/jama.2010.752","volume":"304","author":"EY Chiao","year":"2010","unstructured":"Chiao EY, Dezube BJ, Krown SE, Wachsman W, Brock MV, Giordano TP, Mitsuyasu R, Pantanowitz L (2010) Time for oncologists to opt in for routine opt-out HIV testing? JAMA. 304(3):334\u2013339","journal-title":"JAMA."},{"issue":"10","key":"6116_CR40","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1634\/theoncologist.2016-0107","volume":"21","author":"L Merz","year":"2016","unstructured":"Merz L, Zimmermann S, Peters S, Cavassini M, Darling KE (2016) Investigating barriers in HIV-testing oncology patients: the IBITOP study, Phase I. Oncologist. 21(10):1176\u20131182","journal-title":"Oncologist."},{"issue":"3","key":"6116_CR41","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/imj.14641","volume":"50","author":"YD Lin","year":"2020","unstructured":"Lin YD, Eades L, Nair A, Korman TM, Woolley I (2020) Review of HIV testing recommendations in Australian specialty guidelines for HIV indicator conditions: a missed opportunity for recommending testing? Intern Med J 50(3):293\u2013298","journal-title":"Intern Med J"},{"issue":"2","key":"6116_CR42","doi-asserted-by":"publisher","first-page":"1700157","DOI":"10.1183\/13993003.00157-2017","volume":"50","author":"CC Dobler","year":"2017","unstructured":"Dobler CC, Cheung K, Nguyen J, Martin A (2017) Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta-analysis. Eur Respir J 50(2):1700157","journal-title":"Eur Respir J"},{"issue":"9","key":"6116_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-022445","volume":"8","author":"T Hasan","year":"2018","unstructured":"Hasan T, Au E, Chen S, Tong A, Wong G (2018) Screening and prevention for latent tuberculosis in immunosuppressed patients at risk for tuberculosis: a systematic review of clinical practice guidelines. BMJ Open 8(9):e022445","journal-title":"BMJ Open"},{"key":"6116_CR44","doi-asserted-by":"crossref","unstructured":"Dale KD, Trauer JM, Dodd PJ, Houben R, Denholm JT (2018) Estimating the prevalence of latent tuberculosis in a low-incidence setting: Australia. Eur Respir J. 52(6)","DOI":"10.1183\/13993003.01218-2018"},{"key":"6116_CR45","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1186\/s12889-015-2141-3","volume":"15","author":"E Feletto","year":"2015","unstructured":"Feletto E, Sitas F (2015) Quantifying disparities in cancer incidence and mortality of Australian residents of New South Wales (NSW) by place of birth: an ecological study. BMC Public Health 15:823","journal-title":"BMC Public Health"},{"issue":"11","key":"6116_CR46","doi-asserted-by":"publisher","first-page":"759","DOI":"10.2217\/imt-2020-0069","volume":"12","author":"FG Haddad","year":"2020","unstructured":"Haddad FG, Kattan C, Kattan J (2020) Should immune checkpoint inhibitors be contraindicated in lung cancer patients with latent tuberculosis? Immunotherapy. 12(11):759\u2013762","journal-title":"Immunotherapy."},{"issue":"6","key":"6116_CR47","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.4269\/ajtmh.16-0458","volume":"95","author":"A Sanchez-Montalva","year":"2016","unstructured":"Sanchez-Montalva A, Salvador F, Ruiz-Camps I, Barba P, Valcarcel D, Sulleiro E et al (2016) Imported disease screening prior to chemotherapy and bone marrow transplantation for oncohematological malignancies. Am J Trop Med Hyg 95(6):1463\u20131468","journal-title":"Am J Trop Med Hyg"},{"key":"6116_CR48","doi-asserted-by":"publisher","first-page":"607","DOI":"10.5694\/j.1326-5377.2006.tb00726.x","volume":"185","author":"J Martin","year":"2006","unstructured":"Martin J, Mak D (2006) Changing faces: a review of infectious disease screening of refugees by the Migrant Health Unit, Western Australia in 2003 and 2004. Med J Aust 185:607\u2013610","journal-title":"Med J Aust"},{"issue":"4","key":"6116_CR49","first-page":"264","volume":"4","author":"R Speare","year":"2004","unstructured":"Speare R, Durrheim DN (2004) Strongyloides serology--useful for diagnosis and management of strongyloidiasis in rural Indigenous populations, but important gaps in knowledge remain. Rural Remote Health 4(4):264","journal-title":"Rural Remote Health"},{"issue":"2","key":"6116_CR50","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ejim.2007.03.020","volume":"19","author":"M Hornum","year":"2008","unstructured":"Hornum M, Mortensen KL, Kamper AL, Andersen AB (2008) Limitations of the QuantiFERON-TB Gold test in detecting Mycobacterium tuberculosis infection in immunocompromised patients. Eur J Intern Med 19(2):137\u2013139","journal-title":"Eur J Intern Med"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06116-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-021-06116-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06116-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T12:04:32Z","timestamp":1632571472000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-021-06116-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,24]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["6116"],"URL":"https:\/\/doi.org\/10.1007\/s00520-021-06116-w","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2021,3,24]]},"assertion":[{"value":"1 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was approved by Ethics Department, Peter MacCallum Cancer Centre (QA\/64870\/PMCC-2020).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"N\/A","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"N\/A","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"B.W.T is supported by the Australian Government National Health and Medical Research Council Early Career Fellowship, Medical Research Future Fund Emerging Leader Fellowship and Peter MacCallum Foundation Discovery Partner Fellowship. B.W.T has received research funding from Merck Sharp and Dohme, Gilead Sciences and Sanofi-Pasteur and on the advisory board for CSL-Behring. M.A.S. is supported by National Health and Medical Research Council grants 1116876 and 1173791. M.A.S. has received research funding from Merck, F2G, and Gilead, and personal fees from Pfizer and Gilead.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}